Combination drug-device products in Japan are reimbursed based on their primary mode of action, as determined by MHLW. If the drug is primary, the product follows pharmaceutical reimbursement rules; if the device is primary, it follows medical device rules. Chuikyo evaluates clinical effectiveness, safety, & cost-effectiveness for pricing under the NHI framework.
